KENVUE INC.
Kenvue Inc (KVUE) is a consumer-health spin-off that houses a broad portfolio of over‑the‑counter medicines, personal‑care and skin‑care products sold through retail and online channels. With a market capitalisation of about $28.65 billion, the business leans on established household brands that often produce recurring demand and relatively predictable cash flows. Investors should note the trade‑offs: brand strength and geographic diversification can support resilience, but margins are sensitive to commodity, manufacturing and marketing costs, and the company faces competition and regulatory scrutiny in different markets. As a recently listed company, Kenvue’s stock can show volatility while the market judges its standalone prospects. This summary is general educational information, not personalised financial advice; values can rise or fall and past performance is not a guide to the future. Consider your objectives and risk tolerance before making investment decisions.
Why It's Moving
Kenvue Edges Higher Amid Activist Buzz and Undervalued P/E Signals
- Kenvue's P/E ratio of 22.93 trails the personal products industry's 56.89, hinting at undervaluation and room for catch-up growth.
- Starboard's Jeff Smith expressed thrill at owning KVUE at current levels, fueling optimism for operational improvements or strategic alternatives.
- Recent analyst moves include Deutsche Bank trimming price target to $18 from $20, while Canaccord holds Buy, balancing caution with peer outperformance potential.
Kenvue Edges Higher Amid Activist Buzz and Undervalued P/E Signals
- Kenvue's P/E ratio of 22.93 trails the personal products industry's 56.89, hinting at undervaluation and room for catch-up growth.
- Starboard's Jeff Smith expressed thrill at owning KVUE at current levels, fueling optimism for operational improvements or strategic alternatives.
- Recent analyst moves include Deutsche Bank trimming price target to $18 from $20, while Canaccord holds Buy, balancing caution with peer outperformance potential.
When is the next earnings date for KENVUE INC. (KVUE)?
Kenvue (KVUE) is estimated to report its next earnings on Thursday, February 5, 2026, prior to market open, covering the fourth quarter of fiscal 2025. This date aligns with the company's historical pattern of early February releases for Q4 results, though it remains unconfirmed by management. Investors should monitor official announcements for any updates.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Kenvue's stock with a target price of $19.2, indicating modest potential growth.
Financial Health
Kenvue Inc. is producing solid revenue and cash flow, indicating a healthy financial position.
Dividend
Kenvue's dividend yield of 5% is appealing for investors seeking income from their investments. If you invested $1000 you would be paid $50 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring KVUE
Global Pharma Titans | Brazil Healthcare Investment
Brazil's large and innovative pharmaceutical market presents a significant area of interest for those looking at global healthcare trends. This basket provides exposure to leading US and EU-listed pharmaceutical and biotech companies with substantial operations, partnerships, or sales within Brazil.
Published: October 16, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Steady cash flows
Household brands often produce repeat purchases that can support predictable revenue, though margins may fluctuate with input and marketing costs.
Global footprint
Sales across mature and emerging markets diversify exposure; local competition and currencies add complexity for investors to monitor.
Product innovation matters
Investment in new formulations, packaging and digital channels can drive growth, but R&D and marketing spend may pressure near‑term profitability.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
